| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC2404 |
| Trial ID | NCT04480957 |
| Gene therapy-related omics dataset | GTD0320 | GTD0321 | GTD0322 | GTD0323 | GTD0324 | GTD0325 | GTD0326 | GTD0327 | GTD0328 | GTD0329 | GTD0330 | GTD0331 | GTD0332 | GTD0333 | GTD0334 | GTD0335 | GTD0336 | GTD0337 | GTD0338 | GTD0339 | GTD0340 | GTD0341 | GTD0342 | GTD0343 | GTD0344 | GTD0345 |
| Disease | COVID-19 |
| Altered gene | VEEV|S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | ARCT-021 |
| Phase | Phase1|Phase2 |
| Recruitment status | Completed |
| Title | A Phase 1/2 Randomised, Double Blinded, Placebo Controlled, Ascending Dose Study to Assess the Safety, Tolerability, and Immunogenicity of ARCT-021 in Healthy Adult Subjects |
| Year | 2020 |
| Country | Singapore |
| Company sponsor | Arcturus Therapeutics, Inc. |
| Other ID(s) | ARCT-021-01 |
| Vector information | |||
|
|||
| Cohort1: 21 - 55 years | |||||||
|
|||||||
| Cohort2: 56 - 80 years | |||||||
|
|||||||